Health Economics›Neuroendocrine tumor›All lines of therapy

All lines of therapy

Neuroendocrine tumor · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Everolimus and Octreotide Variant #01	—	R 46 352	28d	~16.4 mo	—	~2	~R 92 704 PFS proxy · indirect	1
Lutetium Lu 177 dotatate and Octreotide LAR Variant #01 Partial	—	R 27 992	28d	—	~48.0 mo	~2	~R 55 984 PFS proxy · indirect	3
Octreotide LAR monotherapy Variant #01	—	R 27 992	28d	5.8 mo	84.7 mo	2	R 55 984 PFS proxy	2
Lanreotide monotherapy Variant #01	—	R 20 067	28d	—	—	~2	~R 40 134 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~11.0 mo	—	~2	~R 36 719 PFS proxy · indirect	2
Octreotide monotherapy Variant #04	—	R 15 464	—	—	—	~2	~R 30 928 indirect	—
Temozolomide monotherapy Variant #02	—	R 7 358	14d	~4.0 mo	~16.3 mo	~26	~R 129 994 PFS proxy · indirect	10
Capecitabine and Temozolomide Variant #01	—	R 5 684	28d	—	—	~2	~R 11 369 indirect	—
Doxorubicin and Fluorouracil Variant #01	—	R 585	35d	—	15.7 mo	2	R 1 170 PFS proxy	—
Fluorouracil and Streptozocin Variant #01 Partial	—	R 303	42d	—	24.3 mo	2	R 607 PFS proxy	—
Octreotide and Interferon alfa Variant #01 Partial	—	—	7d	—	—	~2	—	—
Lanreotide and Interferon alfa-2b Variant #01 Partial	—	—	7d	—	—	~2	—	—
Placebo Partial	—	—	—	3.9 mo	—	—	—	2
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	~13.2 mo	—	~48	—	2
Lanreotide LAR monotherapy Variant #01 Partial	—	—	28d	—	—	~4	—	—

15 of 15 regimens shown